BioCentury
ARTICLE | Clinical News

BGB324: Phase Ia data

April 21, 2014 7:00 AM UTC

An open-label Phase Ia trial in 32 healthy volunteers showed that single doses of up to 1.5 g oral BGB324 were well tolerated. Data were presented at the American Association for Cancer Research meeti...